Genprex Execs to Scout Partnerships at BIO Europe Spring 2026
Event summary
- Genprex CEO Ryan Confer and SVP Thomas Gallagher attending BIO Europe Spring 2026 in Lisbon March 23-25.
- Executives to hold one-on-one meetings with biotech, pharma, and finance leaders.
- Conference expected to host 3,700 executives and 20,000 meetings.
- Genprex developing gene therapies for cancer (Reqorsa®) and diabetes (GPX-002).
- Company listed on NASDAQ (GNPX) as clinical-stage gene therapy developer.
The big picture
Genprex's participation in BIO Europe Spring 2026 underscores its push for partnerships to accelerate development of its gene therapy candidates. The conference provides a critical platform for biotech companies to engage with potential collaborators, investors, and industry experts. As a clinical-stage player, Genprex's ability to secure meaningful partnerships could be pivotal in advancing its pipeline and securing future funding.
What we're watching
- Partnership Potential
- Whether Genprex can secure strategic alliances to advance its clinical pipeline.
- Clinical Progress
- The pace at which Genprex advances its lung cancer and diabetes programs.
- Market Positioning
- How Genprex differentiates itself in the competitive gene therapy space.
Related topics